Proteolysis targeting chimeras (PROTACs) are drugs that use cancer cells’ own proteasome to selectively degrade essential tumor-driver molecules through E3 ubiquitin ligase binding. Resistance to PROTAC therapy in cultured cells has been shown to involve genomic alterations in their E3 ligase targets.